3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis
摘要:
Structure-activity relationship studies, focused on identification of the active pharmacophore fragments in a single high-throughput screening calcilytic bit, resulted in the discovery of potent calcium receptor antagonists, substituted 3H-quinazolin-4-ones. (c) 2005 Elsevier Ltd. All rights reserved.
USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER
申请人:Arexis AB
公开号:EP1631295A2
公开(公告)日:2006-03-08
Use of heterocyclic compounds as scce inhibitors
申请人:Linschoten Marcel
公开号:US20060258651A1
公开(公告)日:2006-11-16
The present invention relates to heterocyclic inhibitors of stratum corneum chymotryptic enzyme (SCCE). More particularly, the invention relates to the use of compounds with the formula (I) or (II) for treatment of certain diseases, in particular skin diseases such as pruirtus, as well as cancer such as ovarian cancer.